This company has been acquired
Pardes Biosciences Management
Management criteria checks 1/4
Pardes Biosciences' CEO is Tom Wiggans, appointed in Mar 2022, has a tenure of 1.5 years. total yearly compensation is $5.26M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth $107.99K. The average tenure of the management team and the board of directors is 2.7 years and 2.4 years respectively.
Key information
Tom Wiggans
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 9.9% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.7yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$76m |
| Mar 31 2023 | n/a | n/a | -US$93m |
| Dec 31 2022 | US$5m | US$521k | -US$97m |
Compensation vs Market: Tom's total compensation ($USD5.26M) is above average for companies of similar size in the US market ($USD758.93K).
Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.
CEO
Tom Wiggans (71 yo)
1.5yrs
Tenure
US$5,255,958
Compensation
Mr. Thomas G. Wiggans, also known as Tom, serves as Independent Director at CymaBay Therapeutics, Inc. since April 2021. He serves as an Executive Chairman of Follica, Inc. since January 2021. He serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.5yrs | US$5.26m | 0.082% $ 108.0k | |
| Founder & Director | no data | US$3.52m | 9.35% $ 12.3m | |
| Chief Financial Officer | 2.7yrs | US$1.82m | 0.52% $ 684.2k | |
| General Counsel & Corporate Secretary | 2.7yrs | no data | 0.35% $ 456.1k |
2.7yrs
Average Tenure
56.5yo
Average Age
Experienced Management: PRDS's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.5yrs | US$5.26m | 0.082% $ 108.0k | |
| Founder & Director | 3.6yrs | US$3.52m | 9.35% $ 12.3m | |
| Director | 2.7yrs | US$110.69k | no data | |
| Independent Director | 2.7yrs | US$170.69k | 0.12% $ 152.0k | |
| Independent Director & Member of Scientific Advisory Board | 3.1yrs | US$153.69k | 0.12% $ 152.0k | |
| Independent Director | 2.7yrs | US$163.19k | 2.25% $ 2.9m | |
| Independent Director | less than a year | US$147.00k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$161.19k | 0% $ 0 | |
| Lead Independent Director | less than a year | US$146.94k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$153.69k | 0% $ 0 | |
| Member of Commercial Advisory Board | no data | no data | no data |
2.4yrs
Average Tenure
62.5yo
Average Age
Experienced Board: PRDS's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/01 19:30 |
| End of Day Share Price | 2023/08/30 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pardes Biosciences, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuchen Ding | Jefferies LLC |
| Douglas Buchanan | JMP Securities |
| Roanna Clarissa Ruiz | Leerink Partners LLC |